Hemophilia

We recommend

Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF

4. 11. 2024 Source: Hemophilia

Níže citovaná studie fáze III hodnotila účinnost a bezpečnost 12měsíční profylaxe rekombinantním von Willebrandovým faktorem (rvWF) u 23 pacientů s těžkou von Willebrandovou chorobou (vWD), kteří byli dříve léčeni jen podle potřeby (při výskytu spontánního krvácení) nebo předtím užívali profylaxi vWF získaným z plazmy (pdvWF).

Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?

Podání infuze s koncentrátem aktivovaného protrombinového komplexu (aPCC) při standardizované…

6. 10. 2024 Source: Hemophilia

Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment

With the development of new treatment options for hemophilia, there has also been progress in…

10. 6. 2024 Source: Hemophilia

Articles on this topic

Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A

Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of…

14. 4. 2022 Source: Hemophilia

Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A

Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the…

14. 4. 2022 Source: Hemophilia

Pharmacokinetic Comparison of Two EHL Products in Hemophilia A

According to a Canadian study published last year, certain pharmacokinetic differences were…

8. 2. 2022 Source: Hemophilia

Practical Two-Point Pharmacokinetic Protocol in Hemophilia A

A recently published study confirmed the practicality of a shortened and simple…

31. 1. 2022 Source: Hemophilia

Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures

The possibility of actively preventing severe bleeding after a major cardiac surgical…

22. 11. 2021 Source: Hemophilia

Neutralizing Antibodies Against Emicizumab –⁠ Detailed Analysis Based on a Case Study

Japanese authors investigated the mechanism of reduced efficacy of emicizumab in an adult…

22. 11. 2021 Source: Hemophilia

Cost-Effectiveness of Preparations Used to Stop Bleeding in Patients with AHA

Choosing the right preparation to manage acute bleeding in patients with acquired hemophilia A…

1. 11. 2021 Source: Hemophilia

Risk of Developing Inhibitors in People with Milder Forms of Hemophilia

Moderate and mild hemophilia A differ from the severe form not only in clinical course and…

1. 11. 2021 Source: Hemophilia

Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A

Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for…

15. 9. 2021 Source: Hemophilia

Monitoring of Joint Health is an Important Part of Hemophilia Care

Joint health has become a key aspect of the quality of life for people with hemophilia. The…

18. 8. 2021 Source: Hemophilia

What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?

Recent studies indicate that target trough levels of factor 1–3% during prophylactic treatment...

10. 5. 2021 Source: Hemophilia

cvičení pohyb venku muž cvičící sport protahování senior

Sport and Physical Activity Benefit Hemophiliacs

Sport and physical activity are beneficial for individuals with hemophilia. This statement was…

5. 5. 2021 Source: Hemophilia

International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders

At the end of December 2020, international guidelines for COVID-19 vaccination in people with…

8. 2. 2021 Source: Hemophilia

COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders

The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct…

8. 2. 2021 Source: Hemophilia

Experiences with AHA in Two Czech Centers and Risk Factor Evaluation

This summer, the journal Haemophilia published the results of an analysis of data from a…

18. 11. 2020 Source: Hemophilia

1 2 3